News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dermira (DERM) Reports Second Quarter 2017 Financial Results And Provides Corporate Update



8/8/2017 1:35:26 PM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
MENLO PARK, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today reported financial results for the quarter ended June 30, 2017 and provided an update on its clinical development programs.

“We are committed to bringing differentiated therapies to market to help treat patients who suffer from chronic skin conditions, and great momentum continues across all aspects of our business toward this objective,” said Tom Wiggans, chairman and chief executive officer of Dermira. “I’m delighted that we are one step closer to potentially bringing a new option to the market for patients suffering from moderate-to-severe chronic plaque psoriasis, with the recent CIMZIA regulatory submissions to the FDA and EMA.

Read at GlobeNewswire


comments powered by Disqus
Dermira
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES